bluuebunny/crossref_metadata_2025_split huggingface dataset:
Risk and causes of hospital admission in patients with atrial fibrillation on treatment with oral anticoagulants
Authors: Pannunzio A , Menichelli D , Pignatelli P , Violi F , Brogi T , Lip G Y H , Pastori D 
Published: October 2024

Abstract

Background
Atrial fibrillation (AF) is associated with an increased risk of hospitalisation, although the main reasons for hospital admission and the role of antiarrhythmic drugs are not clarified.

Objective
The aim of our study was to assess the incidence rate and the factors associated with all-cause, cardiovascular and AF-related causes of hospitalisation in patients suffering from AF.

Methods
This is a prospective single-centre ongoing study (ATHERO-AF cohort) which included 2782 patients affected by non-valvular AF on oral anticoagulants. The primary endpoints were all-cause, cardiovascular and AF-related hospitalisation. Cardiac hospitalizations were defined as (non-AF) arrhythmias, acute coronary syndromes, heart failure (HF), systemic embolism, hypertensive urgency, vascular/cardiac surgery. The AF-related hospitalisation was defined as a recurrence of AF in paroxysmal pattern or as a high-rate symptomatic AF episode in persistent/permanent patterns. Multivariable Cox proportional hazards regression analysis was used to calculate the hazard ratio (HR) with 95% Confidence interval (95%CI) for each factor in relation to risk of hospitalisation.

Results
Overall, 43.5% of patients were women with a mean age of 74.6±9.1year. Patients were followed for a mean of 31±26.8 months. We registered 1205 (12.1%/year) hospitalisations for any reason, 533 (5.7%/year) for cardiovascular causes and 180 (2.0%/year) were AF-related hospitalisations (Central illustration). Among the anti-arrhythmic drug use, we highlighted that flecainide and propafenone were associated with AF-related hospitalisations in paroxysmal and in persistent/permanent patterns (HR 1.861, 95%CI 1.116-3.101 and HR 1.947, 95%CI 1.069-3.548, respectively). Amiodarone (HR 3.012, 95%CI 1.835-4.943) and verapamil or diltiazem (HR 2.067, 95%CI 1.117-3.825) were associated with an increased risk of AF-related hospitalisations in persistent/permanent AF pattern. Furthermore, cancer was associated (HR 1.802, 95%CI 1.057-3.070) with increased risk of hospitalisation due to AF-related causes. Conversely, beta-blockers and digoxin were not associated with increased risk of hospital admission.

Conclusions
Hospitalisations of patients with AF are frequent for both cardiovascular and non-cardiovascular causes. Among the AF-related ones, the use of antiarrhythmic drugs emerged as associated with increased risk of hospitalisations, hypothesizing their poor effect in preventing AF episodes. For these reasons, we suggest carefully considering their use, reserving them for symptomatic patients with frequent AF recurrences.Central Illustration
Long-term prognosis in patients undergoing atrial fibrillation ablation
Authors: Kiliszek M , Krzyzanowski K , Uzieblo-Zyczkowska B , Smalc-Stasiak M , Wierzbowski R , Krzesinski P 
Published: October 2024

Abstract

Aims
The aim of the analysis was to assess the risk of atrial fibrillation (AF) recurrence in the long-term observation of contemporary patients undergoing pulmonary vein isolation (PVI), who did not have recurrence during the first year after catheter ablation.

Methods
Retrospective analysis has been performed. Inclusion criteria: (1) the patients undergoing their first PVI in years 2017–2022, (2) the electroanatomical system, contact force catheters and lesion indexes (Ablation Index or Lesion Size Index) were used, (3) no recurrences were observed during the first 12 months of follow-up, and (4) follow-up longer than 12 months was available. Demographic, clinical and echocardiographic data were collected. Follow-up was based on ambulatory visits with ECG/holter monitoring or implanted device interrogation, when available.

Results
A total of 247 patients were included. The median follow-up was 22 months (interquartile range, 16–31 months). After 24 months, ablation efficacy was 84%, and after 36 months, it was 72%. In the univariate Cox regression analysis, age, previous electrical cardioversion, glomerular filtration rate (eGFR) and the presence of coronary artery disease were linked to AF-free survival. Interestingly, nonparoxysmal AF, left atrial (LA) dimension, heart failure, hypertension or diabetes were not linked to the risk of long-term recurrences. In multivariate Cox regression analysis, presence of coronary artery disease and previous electrical cardioversion were independently linked to the risk of long-term recurrence. In 127 (51.4%) patients, information about the presence of low voltage areas (LVA) was available, and in 21 (16.5%) patients in this group, the presence of LVA was found. Survival of patients with LVA was strikingly worse than that of those without (Figure 1), log-rank test p &lt;0.0001.

Conclusions
Patients who had no recurrences within one year after PVI, still have substantial risk of recurrence in the next 2 years. That concerns specially the patients who had LVA in the electroanatomical mapping.
Comparison of procedural analgosedation in patients undergoing pulsed field ablation or cryoballoon ablation for atrial fibrillation
Authors: Wahedi R , Willems S , Jularic M , Hartmann J , Anwar O , Dickow J , Harloff T , Gessler N , Gunawardene M 
Published: October 2024

Abstract

Background
Pulsed field ablation (PFA) has emerged as a novel technology that is increasingly applied for the catheter ablation (CA) of atrial fibrillation (AF) with similar efficacy to established, thermal energy sources. Data solely focussing on analgosedation compared to established single-shot modalities, such as cryoballoon (CB) ablation are scarce.

Aim
The aim of this study was to assess differences of analgosedation requirement, procedural cardiopulmonary stability, and analgosedation-associated complications between PFA and CB ablation.

Methods
This study was a retrospective single-centre comparison of analgosedation in patients with paroxysmal, persistent, and long-standing persistent AF undergoing pulmonary vein isolation (PVI) with either PFA or CB from March 2021 until April 2022. The primary study endpoints were the requirements of analgosedation medications (propofol, midazolam and sufentanyl), cardiorespiratory stability measured as decreases in oxygen saturation and systolic blood pressure and analgosedation-associated complications. Secondary endpoints were acute procedural success, procedure time and overall complication rates.

Results
A total of 100 patients were included {PFA n=50, CB n=50, mean age 66 ± 10.6, 61% male patients, 65% paroxysmal AF). The body weight – and procedure time-adjusted requirement of all analgosedation medications was significantly higher in the PFA group compared to CB {Propofol 0.14 ± 0.04 mg/kg/min in PFA versus 0.11 ± 0.04 mg/kg/min in CB (p=0.001); midazolam 0.00086 ± 0.0004 mg/kg/min in PFA versus 0.00063 ± 0.0003 mg/kg/min in CB (p=0.002) and sufentanyl 0.0013 ± 0.0007 µg/kg/min in PFA versus 0.0008 ± 0.0004 µg/kg/min in CB (p&lt;0.0001)}. Procedural cardiorespiratory stability did not differ between groups (maximum blood pressure decrease PFA 53.4 ± 20.9 mmHg, CB 50.3 ± 18.6 mmHg, P=0.28 and maximum decrease in oxygen saturation: PFA group 4.8 ± 5.3 %, CB group 3.5 ± 2.6 %, P=0.12). Analgosedation-associated complications did not differ between both groups (PFA n=1/50 mild aspiration pneumonia, CB n=0/50, p=0.99). There was no significant difference in acute procedural success (100% n=50/50 in both groups, p&gt;0.99), non-analgosedation associated complications (PFA: n=2/50, 4%, CB: n=1/50, 2%, p=0.99) and procedure times (PFA 75 ± 31, CB 84 ± 32 mins, p=0.18) between groups.

Conclusions
Pulsed field ablation is associated with higher sedation and especially analgesia requirement compared to cryoballoon ablation, however, the safety of analgosedation does not differ significantly to cryoballoon ablation.
The long-term outcome of pulmonary vein isolation in paroxysmal atrial fibrillation is significantly influenced by diabetes mellitus in general as well as by an antidiabetic therapy
Authors: Reichl J , Bourier F , Deisenhofer I , Hessling G , Kolb C , Reents T , Kottmaier M , Lennerz C , Lengauer S , Bahlke F , Erhard N , Telishevska M , Englert F 
Published: October 2024

Abstract

Introduction
Over the last decades pulmonary vein isolation became a cornerstone in the interventional treatment of paroxysmal atrial fibrillation. Postprocedural recurrences of atrial fibrillation are present in patients with and without concomitant cardiovascular diseases.

Purpose
The aim of this study was to assess the influence of diabetes mellitus and an antidiabetic therapy on the long-term outcome, defined as freedom of atrial fibrillation, of pulmonary vein isolation in patients with paroxysmal atrial fibrillation

Methods
All patients underwent pulmonary vein isolation using the combination of a radiofrequency ablation catheter, a pulmonary mapping catheter and a 3D electroanatomic mapping system. Every procedure was carried out according to current clinical and scientific standards. Procedural, clinical and follow-up data were stored for later statistical analysis. All patients received 4 follow-ups in total. In the first 12 postprocedural months patients were followed up after 3, 6 and 12 months. Furthermore, there was one long-term follow-up up to 6 years after the procedure.

Results
A total of n=1282 patients were included in the study. 39.2% of the patients were female and 60,8% were male. At the timepoint of the procedure the mean age was 63.7 years. The mean follow-up time was 2.2 years. For n=1144 of the included patients the presence respectively the absence of diabetes mellitus was documented. 8.0% (n=92) of these patients had the diagnosis of diabetes mellitus, from which 73.9% (n=68) were and 26.1% (n=24) were not under an antidiabetic therapy. Regarding the long-term outcome, patients without diabetes mellitus had significantly better results (log rank p=0.039). The according Kaplan-Meier-Analysis is shown in figure 1. Patients with diabetes mellitus were significantly older (69.5 years) when compared to patients without diabetes mellitus (63.1 years). However, when data was adjusted for age and gender, diabetes mellitus was still an independent, significant predictor of the recurrence of atrial fibrillation after pulmonary vein isolation. In addition, diabetics under an antidiabetic therapy had a significantly better long-term outcome than the untreated ones (log rank p=0.011). Figure 2 shows the according Kaplan-Meier-Analysis.

Conclusion
Diabetes mellitus has a significant influence on the long-term outcome of pulmonary vein isolation in patients with atrial fibrillation (log rank p=0.039). Patients without diabetes mellitus showed significantly better outcomes when compared to patients with diabetes mellitus also when adjusting the data for age and gender. Furthermore, the presence of an antidiabetic therapy in diabetics influences the long-term outcomes significantly (log rank p=0.011).
Prediction of atrial fibrillation recurrence after ablation: the impact of machine learning and recurrence during the blanking period
Authors: Almeida J , Silva-Teixeira R , Aguiar-Neves I , Fonseca P , Barra S , Oliveira M , Goncalves H , Primo J , Fontes-Carvalho R , Martinez J P , Almeida R 
Published: October 2024

Abstract

Introduction
Pulmonary vein isolation is superior to antiarrhythmic drugs for rhythm control in patients with atrial fibrillation (AF). Nevertheless, recurrences within the first year are still significant. Several clinical risk scores were developed to predict AF recurrence; however, despite good results in development cohorts, the results in external validation are usually poor, limiting the general applicability of these scores.

Purpose
We aimed to develop machine learning (ML) models to predict AF recurrences within the first year after catheter ablation and compare their performance with conventional risk scores.

Methods
We used a retrospective dataset of a tertiary hospital center, including all consecutive patients submitted to the first AF ablation between 2017 and 2021. The dataset included 76 features: patient characteristics, medical history, baseline echocardiography, calcium score, procedure variables, and early recurrence (ER) during the 90-day blanking period. The outcome was defined as the occurrence of an electrocardiographically documented late recurrence (LR) of atrial tachycardia/AF &gt; 30s between 3-12 months. Three different supervised ML models (penalized logistic regression, random forests, and XGBoost) were developed on the training cohort, and hyperparameters were tuned using 10-fold cross-validation. A testing dataset was held out to estimate the final performance (25%). The following risk scores were calculated: APPLE, CAAP-AF, and BASE-AF2 (the last includes ER). Areas under the curve (AUC) of receiver operating characteristic curves were compared using DeLong’s test.

Results
679 patients were included: 62.7% males, median age of 59±16 years, and 78.2% with paroxysmal AF. The median time from diagnosis to ablation was 2±4 years. 74.2% underwent radiofrequency ablation and the remaining cryoablation. ER occurred in 12.5%, and most of these patients also experienced LR (68.7 vs 19.6% in those without ER, p&lt;0.001). LR was observed in 25.6%. The XGBoost model showed the best performance with an AUC 0.774, 95% confidence interval (CI) 0.688–0.844) outperforming existing scores (picture 1): APPLE score AUC 0.607, 95% CI 0.562–0.653, p-value&lt;0.001; CAAP-AF score AUC 0.622, 95% CI 0.576–0.668, p-value=0.002; BASE-AF2 AUC 0.628, 95% CI 0.581–0.675, p-value= 0.003. Variable importance analysis showed a significant drop in the performance of the models when ER was not considered, indicating its high importance in predicting LR (picture 2).

Conclusions
Recurrence during the blanking period was the most important predictor of LR in our population. The ML model was superior to conventional risk scores. ML models might be an essential tool to improve the prediction of outcomes and clinical decision-making for optimal follow-up.ROC curvesFeature Importance
Impact of obesity and early recurrence of atrial fibrillation on very late recurrence following cryoballoon pulmonary vein isolation
Authors: Musat D , Park L , Milstein N , Bhatt A , Preminger M , Sichrovsky T , Habibi M , Kochav S , Shaw R , Mittal S 
Published: October 2024

Abstract

Background
Obesity and early recurrence of atrial fibrillation (ERAF) post cryoballoon (CB) pulmonary vein isolation (PVI) both portend a lower 1-year success rate of ablation. Even after an initial successful ablation, about 1/3 of patients develop a very late recurrence (VLR) of AF, defined as the first AF recurrence more than a year after ablation (excluding an initial 90 day blanking period [BP]). The impact of obesity and ERAF on VLR is still unknown.

Purpose
To evaluate the impact of obesity and ERAF on VLR following CB PVI.

Methods
We enrolled consecutive patients with symptomatic AF who underwent CB PVI and had an implantable loop recorder for long-term ECG monitoring. We identified patients who had no AF recurrence (outside the BP) in the first-year post ablation. ERAF was defined as any episode of AF recorded in the first 90 days post ablation. Patients were grouped as either obese (BMI ≥ 30 kg/m2) or non-obese (BMI &lt;30 kg/ m2). AF recurrences after 1-year post-ablation were ascertained using the loop recorder.

Results
From the initial cohort of 210 patients, 109 (52%) patients (64 ± 10 years; 75 [68%] male; 64 [59%] PAF; CHA2DS2-VASc 2.3 ± 1.4, 38 [35%] with obesity and 41 [38%] had ERAF) were AF-free during the first year. During a follow-up of 961 ± 196 days, 51 (47%) patients had VLR. Non-obese patients without ERAF had the best outcome (Figure). In multivariate analysis, obesity and ERAF were the only significant predictors of VLR (Table). As compared to non-obese patients without ERAF, obese patients with ERAF had a 4-fold greater likelihood of VLR.

Conclusions
About 50% of patients have no AF recurrence in the first year after CB PVI. Non-obese patients have the best outcome regardless of ERAF occurrence. On the other hand, obese patients with ERAF almost always have VLR.
Tricuspid regurgitation in atrial fibrillation: correlation to left atrial myopathy and improvement post ablation
Authors: Lee J , Sponder M , Stojkovic S , Riesenhuber M , Hammer A , Hofbauer T , Sulzgruber P , Pickl J , Kastl S , Schoenbauer R 
Published: October 2024

Abstract

Background
Atrial fibrillation (AF) closely correlates to left atrial (LA) myopathy, which in turn can cause functional mitral regurgitation (FMR). The correlation of LA myopathy to tricuspid regurgitation (TR) is still unknown. Data on the dynamic change of TR post AF ablation is still limited.

Purpose
We sought to investigate the correlation of LA myopathy to TR and furthermore if TR can be improved by AF ablation.

Methods
Consecutive patients presenting for first time AF ablation were prospectively enrolled. All patients underwent transthoracic echocardiography at baseline as well as 6 months after the ablation procedure. TR was graded as follows: minimal, mild, moderate and severe (I-IV). All study participants underwent high density bipolar voltagemaps prior to AF ablation to characterize the presence of atrial myopathy.

Results
Our final study cohort consisted of 143 patients (age 64±11 years, 47% female, 48% persistent AF). 15% had no, 21% minimal, 35% mild, 19% moderate and 9% severe TR, respectively. High density maps with 1325±736 mapping points and with an average bipolar voltage of 1.58±0.89mV were created. A significant decline of average LA bipolar voltage was obvious, when comparing patients without TR to any severity level of TR (p=0.015) (Figure 1), however there was no significant difference in LA bipolar voltage, when comparing different TR severity levels (Figure 1). After a follow up of 6 months a significant improvement of TR was observed (p&lt;0.001) with a median level of improvement by one level. 27% had no, 21% minimal, 31% mild, 18% moderate and 2% severe TR, respectively.

Conclusion
In patients presenting for AF ablation TR closely correlates with LA myopathy according to decreased levels of LA bipolar voltage. AF ablation results in highly significant TR level improvement.
Resumption of anticoagulation therapy among Non-Valvular Atrial Fibrillation (NVAF) patients with prior intracranial haemorrhage
Authors: Sun W , Yan B 
Published: October 2024

Abstract

Purpose
Resumption of anticoagulation therapy (OAC) in patients with non-valvular atrial fibrillation (NVAF) suffering from intracranial haemorrhage (ICH) is challenging in clinical practice. The aim of this study was to evaluate impact of resumption of OAC on clinical outcomes in NVAF patients with history of ICH.

Methods
Consecutive patients with NVAF with or without OAC who survived from an index ICH between January 2018 and July 2022 in 16 public hospitals in Hong Kong were identified and analyzed retrospectively. Resumption of OAC was substantiated by new prescription obtained from electronic medical records. Patients were divided into 5 groups: (i) OAC naïve (as reference group); (ii) resume direct oral anticoagulant (DOAC); (iii) resume Vitamin K antagonist (VKA); (iv) discontinue DOAC; (v) discontinue VKA. Risks of ischemic stroke, recurrent ICH and all-cause mortality were estimated for all groups and compared with individuals without OAC, using adjusted sub-distribution hazard ratios (aSHR) derived from Fine and Gray regression models, accounting for death as competing risk, adjusting for components of CHA2DS2VASC and HASBLED scores. Sub-analysis was conducted to compare outcomes between different DOAC agents (i.e, apixaban, dabigatran, edoxaban, rivaroxaban), using VKA as reference among patients who resumed DOAC or VKA.

Results
Of 982 patients who met inclusion criteria (mean age 77.7±10.9, female 40.9%), 39.1% (n=384) were OAC naive, 32.2% (n=316) resumed DOAC, 12.6% (n=124) resumed VKA, 9.0% (n=88) discontinued DOAC and 7.1% (n=70) discontinued VKA. During a median follow-up period of 2.0 (IQR: 0.7-3.5) years, no statistically significant difference in risk of ischemic stroke was observed among 5 groups. Discontinuation of DOAC was associated with markedly higher risk of ischemic stroke (aSHR=8.32 (1.8-39.3)) only among AF patients with CHA2DS2VASC score ≥ 4, Risk of recurrent ICH was higher in patients who resumed VKA (aSHR=1.6(1.0-2.5)). Sub-analysis demonstrated resumption of apixaban was associated with lowest risk of recurrent ICH (aSHR=0.6(0.4-0.9)). Compared to OAC naïve patients, those who resumed DOAC (aSHR=0.5(0.4-0.7)) had lowest risk of all-cause mortality, whereas discontinuation DOAC (aSHR=1.9(0.4-2.5) and VKA (aSHR=1.6(0.2-2.2)) were both associated with increased mortality.

Conclusion
Our real-world data revealed among NVAF patients with prior ICH long term discontinuation of OAC was associated with increased risk of ischemic stroke. Recurrent ICH was highest among patients who resumed VKA and lowest with apixaban.
Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention
Authors: Kitahara H , Tanabe Y , Yamazaki T , Hiraga T , Abe K , Kobayashi Y 
Published: October 2024

Abstract

Background
Underdose (inappropriate low-dose) of direct oral anticoagulants (DOAC) is sometimes prescribed due to concerns of bleeding risk in patients with atrial fibrillation (AF). In AF patients with coronary artery disease requiring percutaneous coronary intervention (PCI), careful treatment is required to prevent bleeding events because of intensive antithrombotic therapy with a combination of oral anticoagulants and antiplatelet agents.

Purpose
The purpose of this study was to investigate the prevalence of underdose of DOAC and its impact on clinical outcomes in AF patients with coronary artery disease undergoing PCI.

Methods
This multicenter observational cohort study enrolled patients with AF on DOAC undergoing PCI between January 2015 and March 2021 at 15 institutions. Appropriateness of DOAC dose was determined according to the manufacturer's labeling recommendations in Japan. Clinical outcomes within 1 year, including major adverse cardiovascular events (MACE), all-cause mortality, ischemic stroke, and major bleeding events, were evaluated.

Results
Of 630 patients enrolled, 168 patients (26.7%) received underdose, 227 (36.0%) received appropriate low-dose, 213 (33.8%) received appropriate standard-dose, and 22 (3.5%) received overdose. Because of the extremely small number of patients in the overdose group, the primary analysis of the present study was a comparison between the underdose group (n=168) and the appropriate dose group (appropriate low-dose and standard-dose groups) (n=440). Although the incidence of MACE, all-cause mortality, and major bleeding events was not significantly different between the 2 groups (log-rank p=0.872, p=0.170, and p=0.725), ischemic stroke more frequently occurred in the underdose group compared with the appropriate dose group (log-rank p=0.010) (Figure 1). The multivariable Cox regression analysis determined underdose of DOAC as an independent predictor for ischemic stroke (adjusted HR 3.288, 95% CI: 1.189-9.088, p=0.022).

Conclusions
Compared with appropriate dose of DOAC, underdose was associated with a higher incidence of ischemic stroke, despite no significant difference in MACE, all-cause mortality, and major bleeding events, in AF patients undergoing PCI.Figure 1